Freshfields Advises SERB Pharmaceuticals on its U.S. Partnership with SFJ Pharmaceuticals

Jun 01, 2023

Posted by Freshfields

Freshfields represented SERB Pharmaceuticals, a global specialty pharmaceutical company, on its agreement with SFJ Pharmaceuticals, a global drug development company, to acquire exclusive US rights to the ticagrelor reversal agent bentracimab from SFJ.

More details about bentracimab and the transaction can be found here: SERB Pharmaceuticals and SFJ Pharmaceuticals announce a U.S. partnership for bentracimab, a ticagrelor reversal agent – SERB Pharmaceuticals

See all Member News